Loading...
•
Dec 31, 2019
Protalix Q4 2019 Earnings Report
Reported financial results for the fourth quarter and full year ended December 31, 2019, and provided a business update on recent corporate and clinical developments.
Key Takeaways
Protalix reported financial results for the fourth quarter and full year ended December 31, 2019. The company is focused on advancing its clinical pipeline, expanding sales in Brazil of Elelyso®, and leveraging commercial opportunities to expand its global footprint in the treatment of Fabry disease.
Expanded on strong foundation and entered into a new phase of development as a world-class recombinant therapeutic company
Positioned for both near- and long-term success
Three ongoing, fully-enrolled Phase III clinical trials of PRX-102
Anticipate BLA submission to the U.S. Food and Drug Administration under the Accelerated Approval pathway next quarter
Protalix
Protalix
Forward Guidance
Protalix anticipates 2020 to be a banner year as they increase focus on advancing clinical pipeline, expanding Elelyso sales in Brazil, and leveraging commercial opportunities to expand global footprint in Fabry disease treatment.
Positive Outlook
- Advancing clinical pipeline
- Expanding sales in Brazil of Elelyso
- Leveraging commercial opportunities to expand global footprint in Fabry disease treatment